Skip to main content
. 2023 May 31;11(7):946–961. doi: 10.1158/2326-6066.CIR-22-0910

Figure 3.

Figure 3. CD20xCD22 CAR T cells display robust tumor control activity in a dose-dependent manner in vivo. A, Schematics showing the design of the disseminated lymphoma model study with Daudi cells. B, Tumor growth control overtime after tumor implantation and CAR T-cell treatment with the indicated constructs using intravenously administered Daudi cells, n = 6 per condition. One-way ANOVA was performed with Tukey correction. Mean ± SEM is shown. C, Representative bioluminescence ventral at day 20 of the study. D, Kaplan–Meier curves showing survival of NSG animals treated with different versions of CD20xCD22 CAR and CD22 CAR T cells. Log-rank Mantel–Cox test was calculated for survival curves. Significant values are indicated. P value definition: *<0.05, **<0.01, ***<0.001, ****<0.0001.

CD20xCD22 CAR T cells display robust tumor control activity in a dose-dependent manner in vivo. A, Schematics showing the design of the disseminated lymphoma model study with Daudi cells. B, Tumor growth control overtime after tumor implantation and CAR T-cell treatment with the indicated constructs using intravenously administered Daudi cells, n = 6 per condition. One-way ANOVA was performed with Tukey correction. Mean ± SEM is shown. C, Representative bioluminescence ventral at day 20 of the study. D, Kaplan–Meier curves showing survival of NSG animals treated with different versions of CD20xCD22 CAR and CD22 CAR T cells. Log-rank Mantel–Cox test was calculated for survival curves. Significant values are indicated. P value definition: *<0.05, **<0.01, ***<0.001, ****<0.0001.